Cargando…

Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages

Background: Tanshinone IIA (TIIA) is the major lipid-soluble active ingredient of the traditional Chinese medicine Salvia miltiorrhiza, which slows down atherosclerosis (AS). However, it remains unclear whether TIIA has the potential to enhance macrophage efferocytosis and thereby improve atheroscle...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiarou, Zhang, Yifan, Feng, Xiaoteng, Du, Min, Li, Sijin, Chang, Xindi, Liu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598641/
https://www.ncbi.nlm.nih.gov/pubmed/37886125
http://dx.doi.org/10.3389/fphar.2023.1233709
_version_ 1785125598517002240
author Wang, Jiarou
Zhang, Yifan
Feng, Xiaoteng
Du, Min
Li, Sijin
Chang, Xindi
Liu, Ping
author_facet Wang, Jiarou
Zhang, Yifan
Feng, Xiaoteng
Du, Min
Li, Sijin
Chang, Xindi
Liu, Ping
author_sort Wang, Jiarou
collection PubMed
description Background: Tanshinone IIA (TIIA) is the major lipid-soluble active ingredient of the traditional Chinese medicine Salvia miltiorrhiza, which slows down atherosclerosis (AS). However, it remains unclear whether TIIA has the potential to enhance macrophage efferocytosis and thereby improve atherosclerosis. Objective: The focus of this examination was to determine if TIIA could reduce lipid accumulation and treat AS by enhancing efferocytosis. Methods: Firstly, we conducted in vivo experiments using LDLR knockout (LDLR(−/−)) mice for a period of 24 weeks, using histopathological staining, immunofluorescence and Western blot experiments to validate from the efficacy and mechanism parts, respectively; in addition, we utilized cells to validate our study again in vitro. The specific experimental design scheme is as follows: In vivo, Western diet-fed LDLR(−/−) mice for 12 weeks were constructed as an AS model, and normal diet-fed LDLR(−/−) mice were taken as a blank control group. The TIIA group and positive control group (atorvastatin, ATO) were intervened for 12 weeks by intraperitoneal injection (15 mg/kg/d) and gavage (1.3 mg/kg/d), respectively. In vitro, RAW264.7 cells were cultured with ox-LDL (50 ug/mL) or ox-LDL (50 ug/mL) + TIIA (20 uM/L or 40 uM/L). Pathological changes in aortic plaques and foam cell formation in RAW264.7 cells were evaluated using Masson and Oil Red O staining, respectively. Biochemical methods were used to detect lipid levels in mice. The immunofluorescence assay was performed to detect apoptotic cells and efferocytosis-related signal expression at the plaques. RT-qPCR and Western blot were carried out to observe the trend change of efferocytosis-related molecules in both mouse aorta and RAW264.7 cells. We also used the neutral red assay to assess RAW264.7 cells’ phagocytic capacity. Results: Compared with the model group, TIIA decreased serum TC, TG, and LDL-C levels (p < 0.01), reduced the relative lumen area of murine aortic lipid-rich plaques (p < 0.01), enhanced the stability of murine aortic plaques (p < 0.01), reduced ox-LDL-induced lipid build-up in RAW264.7 cells (p < 0.01), and upregulated efferocytosis-related molecules expression and enhance the efferocytosis rate of ox-LDL-induced RAW264.7 cells. Conclusion: TIIA might reduce lipid accumulation by enhancing the efferocytosis of macrophages and thus treat AS.
format Online
Article
Text
id pubmed-10598641
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105986412023-10-26 Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages Wang, Jiarou Zhang, Yifan Feng, Xiaoteng Du, Min Li, Sijin Chang, Xindi Liu, Ping Front Pharmacol Pharmacology Background: Tanshinone IIA (TIIA) is the major lipid-soluble active ingredient of the traditional Chinese medicine Salvia miltiorrhiza, which slows down atherosclerosis (AS). However, it remains unclear whether TIIA has the potential to enhance macrophage efferocytosis and thereby improve atherosclerosis. Objective: The focus of this examination was to determine if TIIA could reduce lipid accumulation and treat AS by enhancing efferocytosis. Methods: Firstly, we conducted in vivo experiments using LDLR knockout (LDLR(−/−)) mice for a period of 24 weeks, using histopathological staining, immunofluorescence and Western blot experiments to validate from the efficacy and mechanism parts, respectively; in addition, we utilized cells to validate our study again in vitro. The specific experimental design scheme is as follows: In vivo, Western diet-fed LDLR(−/−) mice for 12 weeks were constructed as an AS model, and normal diet-fed LDLR(−/−) mice were taken as a blank control group. The TIIA group and positive control group (atorvastatin, ATO) were intervened for 12 weeks by intraperitoneal injection (15 mg/kg/d) and gavage (1.3 mg/kg/d), respectively. In vitro, RAW264.7 cells were cultured with ox-LDL (50 ug/mL) or ox-LDL (50 ug/mL) + TIIA (20 uM/L or 40 uM/L). Pathological changes in aortic plaques and foam cell formation in RAW264.7 cells were evaluated using Masson and Oil Red O staining, respectively. Biochemical methods were used to detect lipid levels in mice. The immunofluorescence assay was performed to detect apoptotic cells and efferocytosis-related signal expression at the plaques. RT-qPCR and Western blot were carried out to observe the trend change of efferocytosis-related molecules in both mouse aorta and RAW264.7 cells. We also used the neutral red assay to assess RAW264.7 cells’ phagocytic capacity. Results: Compared with the model group, TIIA decreased serum TC, TG, and LDL-C levels (p < 0.01), reduced the relative lumen area of murine aortic lipid-rich plaques (p < 0.01), enhanced the stability of murine aortic plaques (p < 0.01), reduced ox-LDL-induced lipid build-up in RAW264.7 cells (p < 0.01), and upregulated efferocytosis-related molecules expression and enhance the efferocytosis rate of ox-LDL-induced RAW264.7 cells. Conclusion: TIIA might reduce lipid accumulation by enhancing the efferocytosis of macrophages and thus treat AS. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598641/ /pubmed/37886125 http://dx.doi.org/10.3389/fphar.2023.1233709 Text en Copyright © 2023 Wang, Zhang, Feng, Du, Li, Chang and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Jiarou
Zhang, Yifan
Feng, Xiaoteng
Du, Min
Li, Sijin
Chang, Xindi
Liu, Ping
Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title_full Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title_fullStr Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title_full_unstemmed Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title_short Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
title_sort tanshinone iia alleviates atherosclerosis in ldlr(−/−) mice by regulating efferocytosis of macrophages
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598641/
https://www.ncbi.nlm.nih.gov/pubmed/37886125
http://dx.doi.org/10.3389/fphar.2023.1233709
work_keys_str_mv AT wangjiarou tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT zhangyifan tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT fengxiaoteng tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT dumin tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT lisijin tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT changxindi tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages
AT liuping tanshinoneiiaalleviatesatherosclerosisinldlrmicebyregulatingefferocytosisofmacrophages